James Butrynski, MD
Basic profileWillamette Valley Cancer Institute and Research Center
James Butrynski is an Oncology physician affiliated with Willamette Valley Cancer Institute and Research Center. OpenAlex indexes 73 publications with 4,906 citations (h-index 29); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer
Sponsor: University of Washington
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20242 payments
- Aadi Bioscience, Inc.Program year20241 payment
- Astellas Pharma US IncProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.
Journal of Clinical Oncology
2024 - Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.
Journal of Clinical Oncology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Jeff Sharman, MD
Willamette Valley Cancer Institute and Research Center
Merideth Wendland, MD
Willamette Valley Cancer Institute and Research Center
Christopher Yasenchak, MD
Willamette Valley Cancer Institute and Research Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”